• LAST PRICE
    0.9000
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    --- / 0.9000
  • Day Range
    ---
  • 52 Week Range
    Low 0.0025
    High 9.1000
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 0.6522
TimeVolumeEGRX
01:47 ET78070.7001
02:18 ET11000.85
02:20 ET540900.85
02:27 ET173190.85
02:38 ET49860.85
02:48 ET4690.85
03:26 ET534120.85
03:30 ET66010.85
03:37 ET13550.85
03:48 ET52840.9
03:50 ET54270.9
03:55 ET14010.9
04:00 ET1990.9
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesEGRX
Eagle Pharmaceuticals Inc
11.7M
1.0x
-4.75%
United StatesSGTI
Shengtai Pharmaceutical Inc
10.0
0.0x
---
United StatesSHWZ
Medicine Man Technologies Inc
6.2M
---
---
United StatesLTUS
Lotus Pharmaceuticals Inc
8.9M
0.1x
+42.39%
United StatesCPIX
Cumberland Pharmaceuticals Inc
15.2M
-1.4x
---
United StatesAOXG
Aoxing Pharmaceutical Company Inc
4.9M
-0.8x
---
As of 2024-11-22

Company Information

Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial capabilities. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The Company also has a research and development facility in Cambridge, Massachusetts. The Company has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana. The Company’s subsidiaries include Eagle Biologics, Inc., Eagle Research Lab Limited, Acacia Pharma Group plc, Acacia Pharma Limited and Acacia Pharma Inc.

Contact Information

Headquarters
50 Tice Boulevard, Suite 315WOODCLIFF LAKE, NJ, United States 07677
Phone
201-326-5300
Fax
302-655-5049

Executives

Interim Executive Chairman of the Board, Interim Principal Executive Officer
Michael Graves
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Christopher Krawtschuk
Director
Steven Ratoff
Independent Director
Luciana Borio
Independent Director
Richard Edlin

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$11.7M
Revenue (TTM)
$257.6M
Shares Outstanding
13.0M
Eagle Pharmaceuticals Inc does not pay a dividend.
Beta
0.71
EPS
$0.91
Book Value
$17.94
P/E Ratio
1.0x
Price/Sales (TTM)
0.0
Price/Cash Flow (TTM)
0.4x
Operating Margin
13.98%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.